OptiNose, Inc. (OPTN) EPS Estimated At $-0.74

May 17, 2018 - By Rudy Corcoran

Analysts expect OptiNose, Inc. (NASDAQ:OPTN) to report $-0.74 EPS on June, 12.After having $-0.64 EPS previously, OptiNose, Inc.’s analysts see 15.63 % EPS growth. The stock decreased 4.51% or $1.16 during the last trading session, reaching $24.58. About 597,935 shares traded or 545.79% up from the average. OptiNose, Inc. (NASDAQ:OPTN) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company has market cap of $931.81 million. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It currently has negative earnings. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.

More notable recent OptiNose, Inc. (NASDAQ:OPTN) news were published by: Nasdaq.com which released: “Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018” on May 07, 2018, also Streetinsider.com with their article: “Optinose (OPTN) PT Raised to $30 at BMO Capital” published on May 15, 2018, Nasdaq.com published: “Optinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in …” on April 23, 2018. More interesting news about OptiNose, Inc. (NASDAQ:OPTN) were released by: Digitaljournal.com and their article: “OptiNose, Inc. to Host Earnings Call” published on May 14, 2018 as well as Seekingalpha.com‘s news article titled: “OptiNose, Inc. 2018 Q1 – Results – Earnings Call Slides” with publication date: May 14, 2018.

OptiNose, Inc. (NASDAQ:OPTN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.